Aktuellt
SENASTE
BB Biotech’s investment level decreased in Q4 (103.8% vs 115% limit), with divestments in top holdings as well as exits in five minor portfolio companies. BB Biotech’s is trading at a NAV discount of 11.4% versus its five-year average premium of 9.4%.
LÄS MER
